

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C12N 9/00, A61K 37/48	A1	(11) International Publication Number: WO 95/27045 (43) International Publication Date: 12 October 1995 (12.10.95)
(21) International Application Number: PCT/US94/03420 (22) International Filing Date: 30 March 1994 (30.03.94) (71) Applicant (for all designated States except US): IGEN, INC. [US/US]; 16020 Industrial Drive, Gaithersburg, MD 20877 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): SMITH, Rodger, G. [US/US]; 4660 Milford Court, Jefferson, MD 21755 (US). MOCAFFERTY, John [GB/GB]; 32 Wakelin Avenue, Sawston, Cambridgeshire CB2 (GB). CHISWELL, David [GB/GB]; 1 Sandhill House, Middle Cayston, Bucks MK8 2LD (GB). DARSLEY, Michael, J. [GB/US]; 5905 Halsey Road, Rockville, MD 20851 (US). FITZGERALD, Kevin [GB/GB]; 3 Burnstable Close, Saffron Walder, Essex CB11 3BX (GB). KENTEN, John, H. [GB/US]; 1921 Windjammer Way, Gaithersburg, MD 20879 (US). MARTIN, Mark, T. [US/US]; 9 Prairie Rose Lane, Gaithersburg, MD 20878 (US). TITMAS, Richard, C. [GB/US]; 26001E Brigadier Place, Damascus, MD 20872 (US). WILLIAMS, Richard, O. [US/US]; 9408 Althea Court, Potomac, MD 20854 (US). (74) Agent: RYAN, John, W.; Igen, Inc., 16020 Industrial Drive, Gaithersburg, MD 20877 (US).		(81) Designated States: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: THE ISOLATION AND PRODUCTION OF CATALYTIC ANTIBODIES USING PHAGE TECHNOLOGY (57) Abstract Disclosed and claimed are methods for producing catalytic antibodies, including human catalytic antibodies, from bacteriophage. The methods require the cloning, selection, screening, and isolation of catalytic antibodies. Also disclosed and claimed are the products themselves, the catalytic antibodies, made from the phage technology. In addition, catalytic antibodies produced from the phage technology and useful in prodrug activation are disclosed and claimed. And finally, the invention also understands the production of catalytic antibodies to phosphonates.		